Ng Joanna K M, Li Joshua J X, Lai Billy S W, Tsang Julia Y, Chan Agnes W S, Cheung Christina M T, Ip Edric C C, Tse Gary M
Department of Anatomical and Cellular Pathology, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong.
Department of Pathology, North District Hospital, Hong Kong.
Hum Pathol. 2023 May;135:76-83. doi: 10.1016/j.humpath.2023.01.005. Epub 2023 Feb 3.
WT1 immunostain is expressed in various benign and malignant neoplasms, as well as normal myoepithelial cells. WT1 shows differential expression in non-neoplastic, benign, and malignant neoplastic myoepithelial cells of the salivary gland. In this study, WT1 immunostain and other myoepithelial markers were compared to investigate the value of WT1 as a myoepithelial marker, and to delineate the expression profile of WT1 in nonsalivary gland myoepithelial cells. WT1, p63, and calponin immunostains were performed on normal and lesional tissues from the breast (adenosis, sclerosing adenosis, lactating adenoma, nipple adenoma, tubular adenoma, adenomyoepithelioma, and adenoid cystic carcinoma [ACC]), skin (cutaneous mixed tumor, hidradenoma, spiradenoma, and ACC), and salivary gland (pleomorphic adenoma and ACC). The stained slides were digitized and orientated with H&E images and assessed simultaneously using QuPath. A total of 129, 58, and 56 breast, cutaneous, and salivary gland lesions, respectively, were included. There was poor agreement between WT1-p63 and WT1-calponin (κ < 0.1) in all organs, with absence of WT1 expression in normal salivary gland myoepithelium and most ACCs. There were no significant differences in WT1 expression in myoepithelial cells in normal breast tissue and benign breast neoplasms. Compared to pleomorphic adenomas, cutaneous mixed tumors showed lower WT1 expression (P < .001). WT1 is a less sensitive myoepithelial marker than calponin and p63. However, its unique pattern of expression in salivary gland primary for pleomorphic adenomas/cutaneous mixed tumor can favor a diagnosis of benign salivary gland tumors, particularly in small biopsy specimens.
WT1免疫染色在各种良性和恶性肿瘤以及正常肌上皮细胞中均有表达。WT1在唾液腺的非肿瘤性、良性和恶性肿瘤性肌上皮细胞中表现出差异表达。在本研究中，比较了WT1免疫染色和其他肌上皮标志物，以研究WT1作为肌上皮标志物的价值，并描绘WT1在非唾液腺肌上皮细胞中的表达谱。对来自乳腺（腺病、硬化性腺病、泌乳性腺瘤、乳头腺瘤、管状腺瘤、腺肌上皮瘤和腺样囊性癌[ACC]）、皮肤（皮肤混合瘤、汗腺腺瘤、螺旋腺瘤和ACC）和唾液腺（多形性腺瘤和ACC）的正常和病变组织进行WT1、p63和钙调蛋白免疫染色。将染色玻片数字化并与苏木精-伊红（H&E）图像对齐，同时使用QuPath进行评估。分别纳入了129个乳腺病变、58个皮肤病变和56个唾液腺病变。在所有器官中，WT1-p63和WT1-钙调蛋白之间的一致性较差（κ<0.1），正常唾液腺肌上皮和大多数ACC中无WT1表达。正常乳腺组织和良性乳腺肿瘤的肌上皮细胞中WT1表达无显著差异。与多形性腺瘤相比，皮肤混合瘤的WT1表达较低（P<0.001）。WT1是一种比钙调蛋白和p63敏感性更低的肌上皮标志物。然而，其在多形性腺瘤/皮肤混合瘤的唾液腺原发灶中独特的表达模式有助于良性唾液腺肿瘤的诊断，尤其是在小活检标本中。
